<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131023">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780077</url>
  </required_header>
  <id_info>
    <org_study_id>RXI-109-1202</org_study_id>
    <nct_id>NCT01780077</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109</brief_title>
  <official_title>A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RXi Pharmaceuticals, Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RXi Pharmaceuticals, Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and tolerability of multiple (3)
      intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy
      volunteers.  The effect of RXI-109 versus placebo on scarring at these incision sites will
      be evaluated visually, histologically, and by biomarker analysis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the safety and tolerability of multiple intradermal administrations of RXI-109</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate safety and tolerability of multiple administrations of RXI-109 at the site of intradermal injection.  Examine and assess any and all local and systemic toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of multiple intradermal administrations of RXI-109 on scar formation</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess visual outcome and histology of scars.  Digital images of the RXI-109 and placebo-treated incisions/scars will be captured and scored.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the timeline and levels of biomarkers</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis of immunohistochemical analysis of biomarkers common to the scar formation pathway.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cicatrix</condition>
  <condition>Scar Prevention</condition>
  <arm_group>
    <arm_group_label>RXI-109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXI-109</intervention_name>
    <description>Multiple intradermal injections of RXI-109 at incision sites</description>
    <arm_group_label>RXI-109</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple intradermal injections of placebo at incision sites</description>
    <arm_group_label>RXI-109</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 21-50 years of age

          -  General good health; if female not pregnant or lactating

          -  Phototype 3 and above based on the Fitzpatrick scale.

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Use of tobacco or nicotine-containing products within 1 month prior to enrollment and
             while on study

          -  Type 1 or 2 diabetes mellitus

          -  A history or presence of any medical condition or therapy that would make the subject
             an unsafe candidate in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Honduras</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scar</keyword>
  <keyword>Scar prevention</keyword>
  <keyword>Fibrosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
